Rare Disease Commercialization and M&A Drive Mid-Cap Biotech Growth
Key Takeaways
- Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation.
- Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
Mentioned
Key Intelligence
Key Facts
- 1Mirum Pharmaceuticals reported a 55% year-over-year revenue increase to $521 million in 2025.
- 2Alkermes completed the acquisition of Avadel for $775 million in cash and a $1.53 billion term loan.
- 3Acadia Pharmaceuticals reached $1.08 billion in annual revenue, driven by a 16% growth in its rare disease portfolio.
- 4Soleno Therapeutics achieved $190.4 million in revenue from VICAT XR in less than nine months of commercial sales.
- 5MiMedx generated $118 million in Q4 revenue, growing 27% despite new Medicare price caps on skin substitutes.
- 6Veracyte's testing volume grew 16% to 45,500 tests, with Decipher revenue increasing by 27%.
| Company | |||
|---|---|---|---|
| Alkermes | $1.50B | 9% | VIVITROL / LUMRIZE |
| Acadia | $1.08B | 14% | DAYBUE / NUPLAZID |
| Mirum | $521M | 55% | Livmarli |
| Soleno | $190.4M | N/A (New Launch) | VICAT XR |
| Veracyte | $570M (Est.) | 19% | Decipher / Afirma |
Who's Affected
Analysis
The fourth quarter of 2025 has marked a pivotal transition for the mid-cap biotechnology and specialty pharmaceutical sectors, moving from a period of heavy clinical investment to one of robust commercial execution. This shift is most evident in the rare disease and neuroscience segments, where companies like Mirum Pharmaceuticals, Acadia Pharmaceuticals, and Soleno Therapeutics have reported significant revenue milestones. The overarching trend across these earnings reports is the successful scaling of orphan drugs and the use of strategic M&A to solidify market positions, even as companies navigate a complex regulatory and reimbursement landscape.
Alkermes has emerged as a primary mover in the sector’s consolidation trend, completing its acquisition of Avadel in February 2026. This $775 million cash transaction, supported by a $1.53 billion term loan, significantly expands Alkermes’ neuroscience footprint by adding the narcolepsy treatment LUMRIZE to its proprietary portfolio. With 2025 revenues reaching nearly $1.5 billion and a 9% growth in its proprietary products like VIVITROL and ARISTADA, Alkermes is positioning itself as a diversified powerhouse. The integration of Avadel is expected to be a major growth lever for 2026, with guidance suggesting proprietary product sales could reach as high as $1.6 billion.
This $775 million cash transaction, supported by a $1.53 billion term loan, significantly expands Alkermes’ neuroscience footprint by adding the narcolepsy treatment LUMRIZE to its proprietary portfolio.
In the rare disease space, Mirum Pharmaceuticals demonstrated the power of commercial focus, reporting a 55% surge in annual revenue to $521 million. The growth was primarily driven by Livmarli, which saw strong uptake in both U.S. and international markets. Mirum’s ability to exceed its own guidance while achieving positive operating cash flow in 2025 serves as a blueprint for other orphan drug developers. The company is now pivoting toward its next phase of growth, with four registrational data readouts expected in the next 18 months, including the Phase III brolobitug program. Similarly, Acadia Pharmaceuticals surpassed the $1 billion annual revenue milestone, fueled by a 16% growth in its Rett syndrome treatment, DAYBUE, and steady demand for NUPLAZID. Acadia’s expansion of its field force by 30% indicates a long-term commitment to capturing the broader prescriber market.
Soleno Therapeutics provided a compelling look at the early stages of a high-potential launch. Its treatment for Prader-Willi syndrome, VICAT XR, generated $190.4 million in its first nine months of commercial availability. With over 1,250 patient start forms—representing roughly 12.5% of the addressable U.S. market—Soleno has rapidly transitioned from a clinical-stage entity to a profitable commercial player, reporting $20.9 million in net income for the year. The company’s focus is now shifting to Europe, with a regulatory decision from the EMA expected in mid-2026, which could significantly expand its global footprint.
What to Watch
However, the sector is not without its challenges, particularly regarding reimbursement and shifting product mixes. MiMedx reported impressive 27% revenue growth, yet management highlighted the impact of new Medicare price caps for skin substitutes. While the company’s surgical segment grew by 25%, the wound care market is facing disruptions as providers adjust to the $127 per square centimeter price ceiling. Meanwhile, RxSight’s 19% revenue decline highlights the volatility inherent in MedTech capital equipment sales, though its high-margin Light Adjustable Lenses (LAL) now account for 86% of its revenue mix, suggesting a more stable recurring revenue model moving forward.
Looking ahead, the biotech sector appears resilient, with many companies holding strong cash positions to weather potential macro volatility. Veracyte’s 19% growth in diagnostic testing and LivaNova’s double-digit growth in cardiopulmonary revenue further underscore the broad-based recovery in healthcare utilization. Investors should watch for the integration of newly acquired assets and the outcome of several high-stakes regulatory decisions in 2026, which will determine if this momentum can be sustained into the next fiscal year.